カテゴリー： Grand View Research, 世界, 医療/バイオ

世界の頭頸部がん治療薬市場2022-2030：治療種類別（化学療法、免疫療法、標的療法）、投与経路別、流通チャネル別、地域別

【英語タイトル】Head And Neck Cancer Therapeutics Market Size, Share & Trends Analysis Report By Therapy Type (Chemotherapy, Immunotherapy, Targeted Therapy), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2022 - 2030

Grand View Researchが出版した調査資料（GRV22DV079）・商品コード：GRV22DV079
・発行会社（調査会社）：Grand View Research
・発行日：2022年11月3日
・ページ数：120
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：グローバル
・産業分野：医薬品
◆販売価格オプション（消費税別）
Single UserUSD5,950 ⇒換算￥868,700見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算￥1,014,700見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算￥1,306,700見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
Grand View Research社は、世界の頭頸部がん治療薬市場規模が、2022年から2030年の間にCAGR 12.5％成長し、2030年までに35億ドルへ達すると予測しています。当調査レポートでは、頭頸部がん治療薬の世界市場を調査対象とし、調査手法・範囲、エグゼクティブサマリー、市場変動・動向・範囲、消費者行動分析、治療種類別（化学療法、免疫療法、標的療法）分析、投与経路別（注射、経口）分析、流通チャネル別（小売・専門薬局、病院薬局、オンライン薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競合分析などを整理しました。なお、当レポートに掲載されている企業情報には、Eli Lilly and Company、Sanofi、Merck & Co., Inc.、Clingen Group plc.、Bristol-Mayers Squibb Company、Takeda Pharmaceutical Company Limited、Teva Pharmaceutical Industries Ltd、F. Hoffmann-La Roche Ltd.などが含まれています。
・調査手法・範囲
・エグゼクティブサマリー
・市場変動・動向・範囲
・消費者行動分析
・世界の頭頸部がん治療薬市場規模：治療種類別
- 化学療法の市場規模
- 免疫療法の市場規模
- 標的療法の市場規模
・世界の頭頸部がん治療薬市場規模：投与経路別
- 注射頭頸部がん治療薬の市場規模
- 経口頭頸部がん治療薬の市場規模
・世界の頭頸部がん治療薬市場規模：流通チャネル別
- 小売・専門薬局チャネルの市場規模
- 病院薬局チャネルの市場規模
- オンライン薬局チャネルの市場規模
・世界の頭頸部がん治療薬市場規模：地域別
- 北米の頭頸部がん治療薬市場規模
- ヨーロッパの頭頸部がん治療薬市場規模
- アジア太平洋の頭頸部がん治療薬市場規模
- 中南米の頭頸部がん治療薬市場規模
- 中東・アフリカの頭頸部がん治療薬市場規模
・競合分析
❖ レポートの概要 ❖

Head And Neck Cancer Therapeutics Market Growth & Trends

The global head and neck cancer therapeutics market size is expected to reach USD 3.5 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 12.5% from 2022 to 2030. Increasing advancements in the diagnosis and treatment of head and neck cancer (HNC) are anticipated to propel market growth, as they are cost-effective and more specific to target over surgeries. The increasing prevalence of different types of HNCs and the growing geriatric population are major drivers of the market.

According to the Cancer Research Institute, in 2021, approximately 54,000 people were diagnosed with different types of HNC and about 11,000 deaths were reported in the U.S. Heavy alcohol consumption, prolonged sun exposure, cancer-causing viral infection such as Epstein-Barr virus (EBV) and tobacco consumption are some of the major factors contribute to rising incidence of various head and neck cancers worldwide.

Furthermore, according to the United Nations, it was estimated that, in 2020, there were around 727 million people aged 60 years and above worldwide. In addition, the geriatric population is expected to increase from 9.3% in 2020 to 16% in 2050. Aging weakens the immune system and makes people susceptible to different types HNCs, consequently, increasing the demand for therapeutic drugs for the treatment of disease.

Moreover, an increase in R&D activities for the development of novel targeted drugs and a multidisciplinary therapeutic approach is expected to lead to an increased survival rate of patients suffering from head and neck cancers. For instance, Merck/Debiopharm’s Xevinapant is currently in phase III clinical trials for the treatment of squamous head and neck cancer. It has received breakthrough therapy designation from the U.S. FDA.

Supportive reimbursement policies are also expected to drive market growth. Several organizations provide financial assistance to patients and their caregivers for purchasing medicines. For instance, in July 2022, British Colombia Cancer included Capecitabine, Carboplatin, Cetuximab, Cisplatin, Docetaxel, Doxorubicin, Fluorouracil, and Leucovorin Calcium in their benefit drug list. Drugs included in this list are applicable for reimbursement for approved indications.

Head And Neck Cancer Therapeutics Market Report Highlights

• By therapy type, the immunotherapy segment held the largest market share in 2021 due to the presence of supportive reimbursement policies and the higher efficacy of immunotherapy drugs as an effective treatment for head and neck cancer diseases

• By route of administration, the oral segment is expected to be the fastest-growing segment during the forecast period. This can be attributed to the high safety, efficacy, and tolerability associated with this route of administration among rare disease patients

• By distribution channel, the retail and specialty pharmacy segment dominated the market in 2021. This dominance can be attributed to the preference of oncologists for specialty pharmacies. Oncologists often need specialty pharmacies so that with extensive therapeutic knowledge, they can support treatment plans and relieve them from the administrative burden

• Asia Pacific is expected to be the fastest-growing region during the forecast period. The growth of the region can be attributed to the entry of new products into the region. For instance, in 2020, NMPA approved ERBITUX (Cetuximab) developed by Merck and Co., Inc., to treat patients with head and neck cancer in China

❖ レポートの目次 ❖

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation
1.1.1 Segment scope
1.1.2 Regional scope
1.1.3 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity flow approach
1.6.1.2 Approach 2: Country wise market estimation using bottom up approach
1.6.1.3 Approach 3: Country wise market estimation using top down approach
1.7 Global Market: CAGR Calculation
1.8 Research Assumptions
1.9 Key KoL Responses
1.10 Market Share Calculations
1.11 List of Secondary Sources
1.12 Objectives
1.12.1 Objective 1:
1.12.2 Objective 2:
1.13 List of Abbreviations
Chapter 2 Executive Summary
2.1 Market Summary
Chapter 3 Head and Neck Cancer Therapeutics Market – Industry Outlook
3.1 Market Lineage Outlook
3.1.1 Parent Market Lineage Outlook
3.1.2 Related/Ancillary Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market Drivers Analysis
3.3.1.1 Increasing prevalence of head and neck cancers
3.3.1.2 Rising geriatric population
3.3.1.3 Increasing R&D and strong presence of pipeline product
3.3.1.4 Supportive reimbursment policies and rising awareness about disease
3.3.2 Market Restraint Analysis
3.3.2.1 Paucity of data related to safety and efficacy
3.3.2.2 High cost of treatments
3.4 Head and Neck Cancer Therapeutics Market Analysis Tools
3.4.2 Industry Analysis – Porter’s
3.4.3 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
3.4.3.1 Political and Legal
3.4.3.2 Economic & Social
3.4.3.3 Technological
3.5 Reimbursement & Regulatory Scenario
3.5.1 North America
3.5.1 Europe
3.5.2 Asia Pacific
3.5.3 Latin America
3.5.4 MEA
3.6 Major Deals & Strategic Alliances
3.6.1 New Product Launch
3.6.2 Acquisition
3.6.3 Expansion
3.6.4 Partnerships
3.7 Pipeline analysis
Chapter 4 Head and Neck Cancer Therapeutics Market Analysis: Therapy Type Scope, 2018 – 2030 (Revenue, USD Million)
4.1 Head and Neck Cancer Therapeutics Market: Therapy Type Movement Analysis
4.2 Chemotherapy
4.2.1 Chemotherapy market estimates and forecast, 2018 – 2030 (USD million)
4.3 Immunotherapy
4.3.1 Immunotherapy market estimates and forecast, 2018 – 2030 (USD million)
4.4 Targeted Therapy
4.4.1 Targeted therapy market estimates and forecast, 2018 – 2030 (USD million)
Chapter 5 Head and Neck Cancer Therapeutics Market Analysis: Route of Administration Scope, 2018 – 2030 (Revenue, USD Million)
5.1 Head and Neck Cancer Therapeutics Market: Route of Administration Movement Analysis
5.2 Injectables
5.2.1 Injectables market estimates and forecast, 2018 – 2030 (USD million)
5.3 Oral
5.3.1 Oral market estimates and forecast, 2018 – 2030 (USD million)
Chapter 6 Head and Neck Cancer Therapeutics Market Analysis: Distribution Channel Scope, 2018 – 2030 (Revenue, USD Million)
6.1 Head and Neck Cancer Therapeutics Market: Distribution Channel Movement Analysis
6.2 Retail & Specialty Pharmacies
6.2.1 Retail & specialty pharmacies market estimates and forecast, 2018 – 2030 (USD million)
6.3 Hospital Pharmacies
6.3.1 Hospital pharmacies market estimates and forecast, 2018 – 2030 (USD million)
6.4 Online Pharmacies
6.4.1 Online pharmacies market estimates and forecast, 2018 – 2030 (USD million)
Chapter 7 Head and Neck Cancer Therapeutics Market Analysis, Regional Scope, 2017-2030, (Revenue, USD Million)
7.1 Market Share Analysis by Regional, 2021 & 2030
7.1.1 North America
7.1.1.1 North America market estimates and forecast, 2018 – 2030 (USD Million)
7.1.1.2 U.S.
7.1.1.2.1 U.S. market estimates and forecast, 2018 – 2030 (USD Million)
7.1.1.3 Canada
7.1.1.3.1 Canada market estimates and forecast, 2018 – 2030 (USD Million)
7.1.2 Europe
7.1.2.1 Europe market estimates and forecast, 2018 – 2030 (USD Million)
7.1.2.2 U.K.
7.1.2.2.1 U.K. market estimates and forecast, 2018 – 2030 (USD Million)
7.1.2.3 Germany
7.1.2.3.1 Germany market estimates and forecast, 2018 – 2030 (USD Million)
7.1.2.4 France
7.1.2.4.1 France market estimates and forecast, 2018 – 2030 (USD Million)
7.1.2.5 Italy
7.1.2.5.1 Italy market estimates and forecast, 2018 – 2030 (USD Million)
7.1.2.6 Spain
7.1.2.6.1 Spain market estimates and forecast, 2018 – 2030 (USD Million)
7.1.3 Asia Pacific
7.1.3.1 Asia Pacific market estimates and forecast, 2018 – 2030 (USD Million)
7.1.3.2 Japan
7.1.3.2.1 Japan market estimates and forecast, 2018 – 2030 (USD Million)
7.1.3.3 China
7.1.3.3.1 China market estimates and forecast, 2018 – 2030 (USD Million)
7.1.3.4 India
7.1.3.4.1 India market estimates and forecast, 2018 – 2030 (USD Million)
7.1.3.5 Australia
7.1.3.5.1 Australia market estimates and forecast, 2018 – 2030 (USD Million)
7.1.3.6 South Korea
7.1.3.6.1 South Korea market estimates and forecast, 2018 – 2030 (USD Million)
7.1.4 Latin America
7.1.4.1 Latin America market estimates and forecast, 2018 – 2030 (USD Million)
7.1.4.2 Brazil
7.1.4.2.1 Brazil market estimates and forecast, 2018 – 2030 (USD Million)
7.1.3.3 Mexico
7.1.3.3.1 Mexico market estimates and forecast, 2018 – 2030 (USD Million)
7.1.3.4 Argentina
7.1.3.4.1 Argentina market estimates and forecast, 2018 – 2030 (USD Million)
7.1.5 Middle East and Africa (MEA)
7.1.8.1 Middle East & Africa market estimates and forecast, 2018 – 2030 (USD Million)
7.1.8.2 South Africa
7.1.8.2.1 South Africa market estimates and forecast, 2018 – 2030 (USD Million)
7.1.3.3 Saudi Arabia
7.1.3.3.1 Saudi Arabia market estimates and forecast, 2018 – 2030 (USD Million)
7.1.3.4 South Africa
7.1.3.4.1 South Africa market estimates and forecast, 2018 – 2030 (USD Million)
Chapter 8 Head and Neck Cancer Therapeutics Market: Competitive Analysis
8.1 Recent Developments and Impact Analysis, by Key Market Participants
8.1.1 Ansoff matrix`
8.2 Company Categorization
8.2.1 Innovators
8.2.2.1 Market Differentiators
8.3 Vendor Landscape
8.3.1 List of Key Distributors And Channel Partners
8.3.2 Key Customers
8.3.3 Key Company Market Share Analysis, 2020
8.4 Public Companies
8.4.1 Comapany Market Position analysis
8.4.2 Competitive dashboard analysis
8.5 Private Companies
8.5.1 List of Key Emerging Companies
8.6 Regional Network Map
8.8 Company Profiles
8.8.1 Eli Lilly and Company
8.8.1.1 Company overview
8.8.1.2 Financial performance
8.8.1.3 Product benchmarking
8.8.1.4 Strategic initiatives
8.8.2 Sanofi
8.8.2.1 Company overview
8.8.2.2 Financial performance
8.8.2.3 Product benchmarking
8.8.2.4 Strategic initiatives
8.8.3 Merck & Co., Inc.
8.8.3.1 Company overview
8.8.3.2 Financial performance
8.8.3.3 Product benchmarking
8.8.3.4 Strategic initiatives
8.8.4 Clingen Group plc.
8.8.4.1 Company overview
8.8.4.2 Financial performance
8.8.4.3 Product benchmarking
8.8.4.4 Strategic initiatives
8.8.5 Bristol-Mayers Squibb Company
8.8.5.1 Company overview
8.8.5.2 Affymetrix
8.8.5.3 Company overview
8.8.5.4 Financial performance
8.8.5.5 Product benchmarking
8.8.5.6 Strategic initiatives
8.8.6 Takeda Pharmaceutical Company Limited
8.8.6.1 Company overview
8.8.6.2 Financial performance
8.8.6.3 Product benchmarking
8.8.6.4 Strategic initiatives
8.8.7 Teva Pharmaceutical Industries Ltd
8.8.7.1 Company overview
8.8.7.2 Financial performance
8.8.7.3 Product benchmarking
8.8.7.4 Strategic initiatives
8.8.8 F. Hoffmann-La Roche Ltd.
8.8.8.1 Company overview
8.8.8.2 Financial performance
8.8.8.3 Product benchmarking
8.8.8.4 Strategic initiatives



★調査レポート[世界の頭頸部がん治療薬市場2022-2030：治療種類別（化学療法、免疫療法、標的療法）、投与経路別、流通チャネル別、地域別] (コード：GRV22DV079)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の頭頸部がん治療薬市場2022-2030：治療種類別（化学療法、免疫療法、標的療法）、投与経路別、流通チャネル別、地域別]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の肝臓転移治療市場2023-2030：治療種類別（化学療法、免疫療法、標的療法）、原発性がん別（大腸がん、乳がん）、流通チャネル別、地域別
    GRV23MR114 / Grand View Research / 2023年2月 / Grand View...
  • 世界の非ホジキンリンパ腫治療薬市場2022-2029：治療種類別（免疫療法、化学療法、標的療法、その他）、疾患種類別、流通チャネル別、地域別
    BZW23AP004 / Bizwit Research & Consulting / 2023年3月20日 / Bizwit Research社では、2021年におよそ83.3億ドルであった世界の非ホジキンリンパ腫治療薬市場規模が、2022年から2029年の間に8.50％以上成長すると予測しています。本調査レポートは、非ホジキンリンパ腫治療薬の世界市場について総合的に調査・分析を行い、エグゼクティブサマリー、市場定義・範囲、市場動向、産業分析、リスク分析（新型コロナウイルス感染症の影響）、治療種類別（免疫療法、化学療法、標的療法、その他）分析、疾患種類別（B細胞リンパ腫、T細胞リンパ腫）分析、流通チャネル別（病院、小売薬局、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、その他）分析、競争分析、調査プロセスなどを掲載しています。なお、本書の主要企業として、Takeda...
  • 世界の小細胞肺がん（SCLC）治療薬市場（2022-2031）：治療種類別（化学療法、標的療法、免疫療法、その他）
    TMR23AP147 / Transparency Market Research / 2023年1月24日 / Transparency Market...
  • 世界の肺がん治療市場（2022-2031）：治療種類別（手術、放射線療法、標的療法、免疫療法、化学療法、その他）
    TMR23AP103 / Transparency Market Research / 2023年1月20日 / Transparency Market...
  • 世界の肝転移治療市場2022-2029：種類別（化学療法、免疫療法、標的療法）、原発がん別、流通チャネル別、地域別
    BZW23AP014 / Bizwit Research & Consulting / 2023年3月20日 / Bizwit Research社では、2021年におよそ12億ドルであった世界の肝転移治療市場規模が、2022年から2029年の間に7.2％以上成長すると予測しています。本調査レポートは、肝転移治療の世界市場について総合的に調査・分析を行い、エグゼクティブサマリー、市場定義・範囲、市場動向、産業分析、リスク分析（新型コロナウイルス感染症の影響）、種類別（化学療法、免疫療法、標的療法）分析、原発がん別（結腸直腸、乳房）分析、流通チャネル別（病院薬局、専門薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、その他）分析、競争分析、調査プロセスなどを掲載しています。なお、本書の主要企業として、F....

    • ◆H&Iグローバルリサーチのお客様（例）◆